Biotalk, Episode 5, Fred Chereau, LogicBio

In this episode of Biotalk, Josh Hamermesh, VP of Locust Walk, spoke to Fred Chereau, CEO of LogicBio, an innovative early-stage gene therapy company that recently completed a $50M financing. During the conversation, Josh and Fred discussed career paths, industry...

Biotalk, Episode 4: Stuart Kliman, Vantage Partners

In this Episode of Biotalk, Locust Walk’s Vice President, Josh Hamermesh, spoke to Stuart Kliman (skliman@vantagepartners.com), Founder and Partner at Vantage Partners, a global management consulting firm that specializes in the areas of negotiation and relationship...

Biotalk, Episode 3: Roger Longman, Real Endpoints

In this episode of BioTalk, Locust Walk’s Vice President, Josh Hamermesh, spoke to Roger Longman, CEO of Real Endpoints, about the pricing and reimbursement issues that are affecting the biopharmaceutical industry, with a particular focus on the impact on deal making....

Biotalk Episode 2: Bradley Campbell, Amicus Therapeutics

In this episode of Biotalk podcast, Josh Hamermesh, Vice President of Locust Walk interviews Bradley Campbell, President & COO of Amicus Therapeutics. Amicus is very much at the forefront developing and commercializing important therapies to treat a range of...

Biotalk. Episode 1: Chris Ehrlich, Locust Walk

Biotalk is a deal maker’s playbook to making an impact and generating returns in life sciences.  Our guest speakers are industry leaders and institutional and family office investors who share their experience and views on deal making and industry trends to educate...